Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?

Download All Articles

A special issue of Journal of Cancer Metastasis and Treatment  (Print ISSN:2394-4722; Online ISSN:2454-2857).

Deadline for manuscript submissions: 31 Dec 2017

Share This Special Issue

Guest Editor(s)

  • Klaus Pors, BEng, PhD, MRSC
    Senior Lecturer in Chemical Biology, Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK.

    Website | E-mail

  • Dr. Jason P. Webber, PhD
    Division of Cancer and Genetics, School of Medicine, Cardiff University, Velindre Cancer Centre, Whitchurch, Cardiff CF14 2TL, UK.

    Website | E-mail

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://mc03.manuscriptcentral.com/jcmt
Submission Deadline: 31 Dec 2017
Contacts: Lijun Jin, Managing Editor, editor001@jcmtjournal.com

Published Articles Download All Articles
  • Introduction of the special issue “How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?”

    Jason P. Webber , Klaus Pors
    This article belongs to the Special Issue How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?
    J Cancer Metastasis Treat 2018;4:45. | doi:10.20517/2394-4722.2018.46
    Published on: 21 Aug 2018  | Viewed:435  | Downloaded:133
    +HTML| PDF
  • Getting better at treating prostate cancer: what clinicians should want from scientists

    Malcolm Mason
    If the treatment landscape for prostate cancer is to be transformed, clinicians and scientists must work together ever more closely. Prostate cancer defeats physicians when patients are not accurately stratified according to patients’ risk of dying of disease, when the effects of tumor heterogeneity are insufficiently understood, and when attempts at therapy by clinicians spur further disease... Read more
    J Cancer Metastasis Treat 2017;3:271-7. | doi:10.20517/2394-4722.2017.51
    Published on: 17 Nov 2017  | Viewed:1435  | Downloaded:90
    +HTML| PDF
  • Getting closer to prostate cancer in patients - what scientists should want from clinicians

    Norman J. Maitland
    For scientists pursuing drug development for prostate cancer, it is critical that an appropriate ex vivo or in vitro model system is available for study. Cancer research has generally consisted of: (1) finding the means to arrest fast growing cancer cells; or (2) (as a compromise) to slow down the excessive rate of cell growth; or in the best case (3) to kill the cancer cells whilst sparing the... Read more
    J Cancer Metastasis Treat 2017;3:262-70. | doi:10.20517/2394-4722.2017.23
    Published on: 17 Nov 2017  | Viewed:1541  | Downloaded:93
    +HTML| PDF
  • Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention

    Agnese C. Pippione , Donatella Boschi , Klaus Pors , Simonetta Oliaro-Bosso , Marco L. Lolli
    Androgens play an important role in prostate cancer (PCa) development and progression. Although androgen deprivation therapy remains the front-line treatment for advanced prostate cancer, patients eventually relapse with the lethal form of the disease. The prostate tumor microenvironment is characterised by elevated tissue androgens that are capable of activating the androgen receptor (AR).... Read more
    J Cancer Metastasis Treat 2017;3:328-61. | doi:10.20517/2394-4722.2017.44
    Published on: 12 Dec 2017  | Viewed:6530  | Downloaded:136
    +HTML| PDF
  • HOX transcription factors and the prostate tumor microenvironment

    Richard Morgan , Hardev S. Pandha
    It is now well established that the tumor microenvironment plays an essential role in the survival, growth, invasion, and spread of cancer through the regulation of angiogenesis and localized immune responses. This review examines the role of the HOX genes, which encode a family of homeodomain-containing transcription factors, in the interaction between prostate tumors and their... Read more
    J Cancer Metastasis Treat 2017;3:278-87. | doi:10.20517/2394-4722.2017.31
    Published on: 6 Dec 2017  | Viewed:2003  | Downloaded:111
    +HTML| PDF
  • Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting

    Robert A. Falconer , Paul M. Loadman
    The membrane-type matrix metalloproteinases (MT-MMPs), an important subgroup of the wider MMP family, demonstrate widespread expression in multiple tumor types, and play key roles in cancer growth, migration, invasion and metastasis. Despite a large body of published research, relatively little information exists regarding evidence for MT-MMP expression and function in metastatic prostate... Read more
    J Cancer Metastasis Treat 2017;3:315-27. | doi:10.20517/2394-4722.2017.40
    Published on: 12 Dec 2017  | Viewed:2693  | Downloaded:136
    +HTML| PDF
  • Prostate cancer exosomes as modulators of the tumor microenvironment

    Alex P. Shephard , Vincent Yeung , Aled Clayton , Jason P. Webber
    Researchers are currently trying to understand why some men with prostate cancer go on to develop aggressive disease whilst others maintain slow growing tumors. Although endogenous genetic anomalies within the tumor cell are important, the prevailing view is that the tissue microenvironment as a whole is the determinant factor. Many studies have focussed on the role of soluble factors in... Read more
    J Cancer Metastasis Treat 2017;3:288-301. | doi:10.20517/2394-4722.2017.32
    Published on: 6 Dec 2017  | Viewed:6109  | Downloaded:348
    +HTML| PDF
  • Tumor heterogeneity and therapy resistance - implications for future treatments of prostate cancer

    Fiona M. Frame , Amanda R. Noble , Sandra Klein , Hannah F. Walker , Rakesh Suman , Richard Kasprowicz , Vin M. Mann , Matt S. Simms , Norman J. Maitland
    Aim: To develop new therapies for prostate cancer, disease heterogeneity must be addressed. This includes patient variation, multi-focal disease, cellular heterogeneity, genomic changes and epigenetic modification. This requires more representative models to be used in more innovative ways. Methods: This study used a panel of cell lines and primary prostate epithelial cell cultures derived from... Read more
    J Cancer Metastasis Treat 2017;3:302-14. | doi:10.20517/2394-4722.2017.34
    Published on: 6 Dec 2017  | Viewed:6219  | Downloaded:339
    +HTML| PDF
  • Current challenges and opportunities in treating hypoxic prostate tumors

    Declan J. McKenna , Rachel Errington , Klaus Pors
    Hypoxia is a well-established characteristic of prostate tumors and is now recognised as a major contributory factor to both tumor progression and increased resistance to therapy. One strategy to target hypoxic tumor cells is the development of hypoxia-activated prodrugs (HAPs), which are activated in low oxygen environments. Several HAPs have been developed but despite encouraging results from... Read more
    This article belongs to the Special Issue How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?
    J Cancer Metastasis Treat 2018;4:11. | doi:10.20517/2394-4722.2017.54
    Published on: 1 Mar 2018  | Viewed:2409  | Downloaded:219
    +HTML| PDF
  • Expression and regulation of aldehyde dehydrogenases in prostate cancer

    Ali I. M. Ibrahim , Maria Sadiq , Fiona M. Frame , Norman J. Maitland , Klaus Pors
    The functional role of aldehyde dehydrogenases (ALDHs) in prostate cancer remains an area of some controversy. Many studies have used high ALDH functional activity to isolate putative cancer stem cells with tumour-initiating and propagating properties, while evidence is also emerging about the involvement of specific isoforms in migration, invasiveness and metastasis. Identification of specific... Read more
    This article belongs to the Special Issue How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?
    J Cancer Metastasis Treat 2018;4:44. | doi:10.20517/2394-4722.2018.07
    Published on: 21 Aug 2018  | Viewed:790  | Downloaded:139
    +HTML| PDF
Journal of Cancer Metastasis and Treatment ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.